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Abstract
Background: Mifepristone (MF) has been largely used in reproductive medicine due to its capacity to modulate
the progesterone receptor (PR). The study of MF has been expanded to the field of oncology; yet it remains
unclear whether the expression of PR is required for MF to act as an anti-cancer agent. Our laboratory has shown
that MF is a potent inhibitor of ovarian cancer cell growth. In this study we questioned whether the growth
inhibitory properties of MF observed in ovarian cancer cells would translate to other cancers of reproductive and
non-reproductive origin and, importantly, whether its efficacy is related to the expression of cognate PR.
Methods: Dose-response experiments were conducted with cancer cell lines of the nervous system, breast,
prostate, ovary, and bone. Cultures were exposed to vehicle or increasing concentrations of MF for 72 h and
analysed for cell number and cell cycle traverse, and hypodiploid DNA content characteristic of apoptotic cell
death. For all cell lines, expression of steroid hormone receptors upon treatment with vehicle or cytostatic doses of
MF for 24 h was studied by Western blot, whereas the activity of the G1/S regulatory protein Cdk2 in both
treatment groups was monitored in vitro by the capacity of Cdk2 to phosphorylate histone H1.
Results: MF growth inhibited all cancer cell lines regardless of tissue of origin and hormone responsiveness, and
reduced the activity of Cdk2. Cancer cells in which MF induced G1 growth arrest were less susceptible to lethality
in the presence of high concentrations of MF, when compared to cancer cells that did not accumulate in G1.
While all cancer cell lines were growth inhibited by MF, only the breast cancer MCF-7 cells expressed cognate PR.
Conclusions: Antiprogestin MF inhibits the growth of different cancer cell lines with a cytostatic effect at lower
concentrations in association with a decline in the activity of the cell cycle regulatory protein Cdk2, and apoptotic
lethality at higher doses in association with increased hypodiploid DNA content. Contrary to common opinion,
growth inhibition of cancer cells by antiprogestin MF is not dependent upon expression of classical, nuclear PR.
Background
While mifepristone (MF) was originally synthesized as
an antiglucocorticoid agent, the realization of its affinity
for the progesterone receptor (PR) expanded its study
and application in the field of reproductive medicine for
early termination of pregnancy, emergency contracep-
tion and menstrual cycle regulation [1,2]. More recently,
MF emerged as a potential treatment of endocrine-
related diseases such as uterine leiomyoma and endome-
triosis [3]. Moreover, the potential use of MF in oncol-
ogy has been promising [4]. Because several tumors of
both gynecologic and non-gynecologic origin are steroid
hormone-dependent and express PR, MF has been
investigated as a potential anti-cancer therapeutic agent
largely based on its capacity to modulate PR. However,
it remains unclear whether the mechanism through
which MF acts to induce cytostasis and lethality in can-
cer cells actually requires PR expression.
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Evidence suggests that the cytostatic effect of MF may
be mediated by an agonistic action on PR. Support for
this idea comes from studies using T47Dco breast can-
cer cells expressing high levels of PR, in which MF
interfered with cell proliferation, displaying progester-
one-like effects [5]. In MDA-MB-231 breast cancer cells
that were transfected with PR, MF, akin to progesterone,
inhibited cell growth by arresting cells in the G1 phase
of the cell cycle [6]. Conversely, there is also evidence
suggesting that the efficacy of MF as an anti-cancer
agent may not require PR expression. Liang and collea-
gues reported that micromolar doses of MF alone were
able to inhibit the growth of ER- and PR-negative
MDA-MB-231 breast cancer cells [7]. Additionally, MF
was capable of inhibiting the growth of LNCaP prostate
cancer cells that were either androgen-sensitive or
-refractory [8], while competition for PR and GR with
equimolar doses of MF and progesterone or hydrocorti-
sone could not reverse the degree of growth inhibition
achieved by MF alone. Furthermore high concentrations
of MF were unable to block growth inhibition induced
by supra-pharmacological doses of progesterone (i.e.
concentrations higher than needed to saturate the cog-
nate PR) in endometrial cancer cells carrying PR [9];
instead high doses of MF potentiated the growth retar-
dation and induction of apoptosis triggered by high
doses of progesterone [10]. Such cytotoxicity of elevated
concentrations of progesterone and MF was also
observed in PR positive MCF-7 breast cancer cells and
PR negative C4-I cervical carcinoma cells [11].These
findings imply that MF may be working independently
of either cognate PR or GR. On the other hand, compe-
tition for GR with an equimolar concentration of dexa-
methasone partially reversed growth inhibition by MF in
the androgen-insensitive PC-3 prostate cancer cells, sug-
gesting a possible role of GR in mediating the growth
inhibitory properties of MF [12]. Altogether, findings
from reports investigating the anticancer properties of
MF as an endocrine-related phenomenon emphasize the
lack of clarity regarding whether the mechanistic action
of MF involves a specific steroid hormone receptor,
although MF is mostly studied for anti-cancer therapy
largely based on its anticipated interaction with PR.
In the few existing reports that investigated the effects
of MF in epithelial ovarian cancer cells, our laboratory
[13-15] and others [16,17], demonstrated the efficacy of
MF as a growth inhibitory agent. We have shown that
MF inhibits the growth of ovarian cancer cells of differ-
ent genetic backgrounds in a dose-dependent manner in
vitro and in vivo [13]. Our inquiry on the molecular
mechanisms underlying MF-induced growth arrest
revealed that ovarian cancer cells cultured in the pre-
sence of a cytostatic concentration of MF had reduced
DNA synthesis and arrested the cell cycle at the G1/S
phase transition [13]. Furthermore, exposure of OV2008
and SK-OV-3 ovarian cancer cells to a cytostatic con-
centration of MF increased the abundance of the cell
cycle inhibitors p21cip1 and p27kip1, decreased the abun-
dance of Cdk2 and cyclin E, and decreased Cdk2 activity
[13]. These results suggested that the cytostatic effect of
MF is mediated through a G1 phase arrest [13]. How-
ever, when we exposed 6 different ovarian cancer cell
lines of different genetic backgrounds and platinum sen-
sitivities to concentrations of MF higher than 20 μM,
the antiprogestin triggered cell death evidenced by an
increase in sub-diploid fragmented DNA content and
cleavage of caspase-3 and of its downstream substrate
PARP [14]. Whether MF-mediated growth inhibition in
ovarian cancer cells require PR remains unclear. The
reported level of expression of PR in ovarian cancer cell
lines is not without controversy. For example, Caov-3
cells were reported to express PR mRNA in one study
[18] but not in another [19]. Similarly, studies in SK-
OV-3 cells showing some or no expression of PR
mRNA and protein have been published [19-23].
Up to this point, the literature has not addressed
whether MF requires PR expression to work as an anti-
cancer agent. In this study we sought to extend our
findings in ovarian cancer cells to cancer cell lines of
alternate tissues of origin, including cancers of both
reproductive and non-reproductive origin, and ques-
tioned whether the expression of PR was related to the
sensitivity of the cancer cells to the growth-inhibitory
influence of MF. We hypothesized that MF would be
capable of growth-inhibiting cancers of reproductive and
non-reproductive origin regardless of PR expression, dis-
playing cytostatic effects at lower micromolar concentra-
tions and lethal effects at higher micromolar doses. We
describe that MF inhibited the growth of 10 different
cancer cell lines originating from the nervous system,
breast, prostate, ovary, and bone, of which only one
expressed cognate PR, suggesting that contrary to com-
mon opinion, the capability of MF to act as a growth
inhibitory agent is unrelated to the expression of classi-
cal, nuclear PR.
Methods
Cell lines and in vitro exposure to MF
The human malignant meningioma IOMM-Lee cells
were kindly provided by Dr. Anita Lal (University of Cali-
fornia, San Francisco), the human malignant glioma
U87MG cells, human osteosarcoma U-2OS and SAOS-2
cells, and estrogen-unresponsive breast carcinoma MDA-
MB-231 cells were from the American Type Culture
Collection (ATCC, Manassas, VA). These cell lines were
maintained in Dulbecco’s Modification of Eagle’s Med-
ium (DMEM) (Mediatech, Herndon, VA) supplemented
with 10% fetal bovine serum (Atlanta Biologicals,
Tieszen et al. BMC Cancer 2011, 11:207
http://www.biomedcentral.com/1471-2407/11/207
Page 2 of 12
Lawrenceville, GA), 10 mM HEPES (Mediatech), 4 mM
L-glutamine (Mediatech), 1 mM sodium pyruvate (Med-
iatech), 100 IU penicillin (Mediatech) and 100 μg/ml
streptomycin (Mediatech). SK-OV-3 and OVCAR-3 ovar-
ian cancer cells were from ATCC, and routinely main-
tained in RPMI 1640 (Mediatech) supplemented with
10% fetal bovine serum (Atlanta Biologicals), 10 mM
HEPES (Mediatech), 4 mM L-glutamine (Mediatech),
0.45% D-(+)-glucose (Sigma Chemical Co., St. Louis,
MO), 1 mM sodium pyruvate (Mediatech), 1 X non-
essential amino acids (Mediatech), 100 IU penicillin
(Mediatech), 100 μg/ml streptomycin (Mediatech), and
0.01 mg/ml human insulin (Roche, Indianapolis, IN). The
androgen-responsive human prostate carcinoma LNCaP
and androgen-unresponsive PC-3 cells were from ATCC
and maintained in RPMI 1640 (Mediatech) supplemented
with 10% fetal bovine serum (Atlanta Biologicals), 10 mM
HEPES (Mediatech), 4 mM L-glutamine (Mediatech), 1
mM sodium pyruvate (Mediatech), 100 IU penicillin
(Mediatech), and 100 μg/ml streptomycin (Mediatech).
The human breast adenocarcinoma MCF-7 cells were
obtained from ATCC and maintained in DMEM (Media-
tech) supplemented with 10% fetal bovine serum (Atlanta
Biologicals), 10 mM HEPES (Mediatech), 4 mM L-gluta-
mine (Mediatech), 1 mM sodium pyruvate (Mediatech),
100 IU penicillin (Mediatech), 100 μg/ml streptomycin
(Mediatech), 1 X non-essential amino acids (Mediatech),
and 0.01 mg/ml human insulin (Roche). All cell lines
were cultured at 37°C in a humidified atmosphere in the
presence of 5% CO2. Treatment of the cells with MF
(Sigma) used a 20,000 μM stock solution of the drug in
DMSO (Mediatech). The maximal concentration of
DMSO in medium was 0.2% (v/v). We have shown pre-
viously that cancer cells responded similarly to micromo-
lar concentrations of MF when cultured in media
without phenol red and charcoal-extracted fetal bovine
serum or media containing unextracted serum and hav-
ing phenol red [13]. Consequently in this work all experi-
ments were conducted using media with unextracted
serum and in the presence of phenol red.
Cell proliferation and doubling times
To measure proliferation in the presence of MF, cells
were seeded into 6-well plates at a density selected to
ensure exponential growth of each cell line while pre-
venting the cells from reaching 100% confluence over
the course of the experiment. Following a period of 24
h allotted for cell adherence, the cells were cultured in
the continuous presence of MF or DMSO for 72 h. Tri-
plicate cultures were trypsinized, pelleted by centrifuga-
tion at 500 g for 5 min, and resuspended in the
appropriate growth medium. An aliquot of each cell sus-
pension was combined with ViaCount reagent (Guava
Technologies, Hayward, CA) resulting in a 1:10 (v/v)
dilution and then studied using the Guava ViaCount
application in the Guava EasyCyte Mini microcapillary
cytometer (Guava Technologies) as we previously
described [15]. The data were acquired and analyzed
using the CytoSoft 4.1 software (Guava Technologies).
When indicated, the concentrations of MF required to
inhibit cell proliferation by 50% or IC50 were determined
using software designed to study drug interaction that
calculates the median effective dose, Dm, which is ana-
logous to the IC50 (Calcusyn, Biosoft, Cambridge, UK).
To obtain cell culture doubling times (DT), cells were
plated at a density equal to that used in dose-response
experiments and allowed to grow in culture for 96 h.
Cells were harvested in triplicate and counted by micro-
cytometry (Guava technologies) every 12 h. A nonlinear
regression analysis designed to estimate the DT of expo-
nentially growing cells was conducted for each growth
curve using Prism 5.0 computer software (GraphPad,
San Diego, CA) and an equation that fits a rate constant
to a data set demonstrating exponential growth. The
rate constant (K) was then used to calculate a value for
DT as follows: DT = ln(2)/K.
Cell cycle analysis
Cells exposed to either vehicle or MF for 72 h were trypsi-
nized, pelleted by centrifugation at 500 g for 5 min, resus-
pended in the appropriate growth medium, and fixed with
4% paraformaldehyde. An aliquot ranging from 40,000-
300,000 cells (varying by treatment and cell line) was then
washed with PBS and pelleted by centrifugation at 500 g
for 5 min. Cells were resuspended in 200 μl of cell cycle
buffer [3.8 mM sodium citrate (Sigma), 7 U/ml RNase A
(Sigma), 0.1% (v/v) Triton X-100 (Sigma), and 0.05 mg/ml
propidium iodide (Sigma)] at a concentration of 200-1,500
cells/μl, and analyzed for the capacity of their DNA to
bind propidium iodide utilizing the Guava EasyCyte Mini
microcapillary cytometer and the cell cycle application of
the CytoSoft 4.1 software.
SDS-PAGE and Western blotting
Cells were scraped, pelleted, and washed twice with PBS,
then snap frozen followed by storage at -80°C. Cells
were lysed by the addition of NP-40 lysis buffer contain-
ing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-
40 (Sigma), 50 mM sodium fluoride (Sigma), 1 mM
PMSF (Sigma), 1 mM dithiothreitol (Invitrogen, Carls-
bad, CA), 2 μg/ml pepstatin (Sigma), 2 μg/ml leupeptin
(Sigma), 2 μg/ml aprotinin (Sigma), and 1 mM orthova-
nadate (Sigma). Lysates were centrifuged at 16,000 g for
20 min at 4°C, and the supernatant was considered the
whole cell extract, which was assayed for protein con-
tent using the bicinchoninic acid method (BCA; Pierce,
Rockford, IL). Whole cell extracts were appropriately
diluted in 3 X concentrated electrophoresis sample
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buffer and boiled for 10 min. Equivalent amounts of
protein (100 or 50 μg) were loaded in fixed 7.5% or 12%
polyacrylamide gels, subjected to SDS-PAGE and trans-
ferred to PVDF membranes. The blots were blocked in
5% (v/v) nonfat milk in TBS containing 0.1% (v/v)
Tween 20 (T), and then probed overnight with primary
antibodies against PR (clone hPRa7; 4 μg/mL; Thermo
Fisher Scientific, Fremont, CA; or #1483-1; 1:1,000; Epi-
tomics, Burlingame, CA), GR (#sc-1003; 1:1,000; Santa
Cruz Biotechnology, Santa Cruz, CA), AR (#1852-1;
1:10,000; Epitomics), ER-a (#4200-1; 1:1,000; Epitomics),
p21cip1 (clone 6B6; 2 μg/mL; BD Biosciences, San Diego,
CA), p27kip1 (clone 57; 1:2,000; BD Transduction
Laboratories, San Diego, CA), cyclin E (clone HE12; 0.5
μg/ml; BD Pharmigen, San Diego, CA), and Cdk2 (M2;
#sc-163; 1:1,000; Santa Cruz Biotechnology). The mem-
branes were washed 3 × 5 min in TBS-T and incubated
with a 1: 10,000 dilution of peroxidase-conjugate sec-
ondary antibody (#111-035-003 or #115-035-003; Jack-
son ImmunoResearch Laboratories, West Grove, PA) for
30 min at room temperature. The blots were again
washed, developed by chemiluminescence, and exposed
to radiographic film. Blots were also probed with an
antibody directed against b-Actin (clone AC-15;
1:20,000; Sigma) to control for protein loading. When
indicated, densitometry was used to compare protein
expression using ImageJ 1.43 software (National Insti-
tutes of Health, Bethesda, MD).
Cdk2 in vitro kinase assay
An aliquot (100 μg of protein) from each NP-40 cell lysate
was incubated overnight at 4°C with constant rotation in 1
ml of NP-40 lysis buffer containing 1 μg polyclonal rabbit
antibody to Cdk2 (M2; #sc-163; Santa Cruz Biotechnol-
ogy). Immunocomplexes associated with Cdk2 were col-
lected after incubating for 2 h with protein A/G PLUS-
Agarose beads (Santa Cruz Biotechnology). The immune
complexes were washed three times with NP-40 lysis buf-
fer and twice with kinase buffer [50 mM HEPES (pH 7.2),
10 mM MgCl2, 1 mM DTT, 10 mM b-glycerophosphate,
and 1 mM sodium fluoride]. Subsequently, the beads were
resuspended in 30 μl of kinase buffer containing 2 μg his-
tone H1 (Upstate Cell Signaling Solutions, Lake Placid,
NY), 5 μM ATP (Upstate), and 5 μCi [g32P]ATP (MP Bio-
medicals; Irvine, CA). The reaction mixtures were incu-
bated at 30°C for 30 min and then terminated with 30 μl
of 2 X electrophoresis sample buffer, boiled, and separated
on 12% SDS-PAGE. Gels were stained with Coomassie
blue (Sigma) to visualize the histone H1 bands, dried, and
autoradiographed.
Statistical analysis
All data are reported as mean ± SEM, and statistical sig-
nificance was defined as P <0.05. To compare cell cycle
kinetics and hypodiploid DNA distribution, one-way
analysis of variance (ANOVA) followed by the Tukey’s
multiple comparison test was used as appropriate.
Results
MF inhibits the growth of tumor cells of the nervous
system, breast, prostate, ovary, and bone
A panel of 10 cancer cell lines was selected to assess the
capacity of MF to inhibit the growth of cancer cells origi-
nating from the nervous system, breast, prostate, ovary
and bone. A series of dose-response experiments was con-
ducted to study the effect of 72 h exposure to MF on cell
growth. In accordance with our hypothesis, MF inhibited
the growth of the entire panel of cancer cells included in
the study in a dose-related manner (Figure 1). We com-
pared the growth inhibitory potency of MF among cell
lines quantitatively by comparing the mean IC50 values
representing at least 3 independent experiments for each
cell line (Table 1). The DT for each cell line was indicated
in the table and its calculation depicted in Additional File
1, Figure S1. Using this method, IOMM-Lee, LNCaP, and
SK-OV-3 cells displayed lower IC50s to MF-induced
growth inhibition while MCF-7, PC-3, OVCAR-3,
U87MG, U-2OS, and SAOS-2 cells responded to MF at
higher IC50s. MDA-MB-231 cells were the least sensitive
to growth inhibition by MF as indicated by the highest
IC50. Overall all cell lines responded to the growth inhibi-
tory effect of MF with IC50s ranging from ~ 9 to 30 μM.
MF induces G1 accumulation in select cancer cell lines
To analyze the effect of MF treatment on cell cycle tra-
verse, each cell line was cultured in the presence of
vehicle or MF for 72 h, harvested, and stained with pro-
pidium iodide; the distribution of cells with DNA con-
tent characteristic of G1, S, or G2/M phases of the cell
cycle, as well as the proportion of cell particles with
hypodiploid DNA content–encompassing particles from
dead cells–was analyzed by microcytometry. Figure 2
represents the cell cycle distributions of all cell lines fol-
lowing exposure to MF. Consistent with our previous
findings in ovarian cancer cells, we observed an accu-
mulation of cells with DNA content representative of
G1 phase in the U87MG, MCF-7, PC-3, and SK-OV-3
lines (Figure 2A). A significant accumulation of cells in
G1 phase was observed at a concentration of 10 μM of
MF in PC-3 cells and of 20 μM of MF in MCF-7 cells.
While statistical significance was not achieved with
U87MG and SK-OV-3 cells, the trend of G1 accumula-
tion was apparent. G1 accumulation occurred in a dose-
dependent manner in these 4 cell lines, with a slight
decrease at a concentration of 40 μM MF corresponding
to an increase in hypodiploid DNA content, indicating
cellular lethality at this high concentration of the steroid
(see below; Figure 3). The accumulation of cells with G1
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DNA content was accompanied by a dose-dependent
decrease in the proportion of cells with DNA content char-
acteristic of S and G2/M phases (Figure 2B and 2C). Alter-
nately, cell cycle distributions of IOMM-Lee, MDA-MB-
231, LNCaP, OVCAR-3, U-2OS and SAOS-2 lines did not
show an apparent accumulation of cells with G1 DNA con-
tent upon 72 h exposure to MF (Figure 2D). Instead, the
proportion of G1 DNA content remained fairly constant at
lower doses of MF and then decreased as these cell lines
became susceptible to the lethality of higher drug concen-
trations. In this subset of cell lines, we also observed a
decrease in the proportion of cells with DNA content char-
acteristic of S and G2/M phases that was most notable at
higher concentrations of MF (Figure 2E and 2F).
Cancer cell lines associated with MF-induced G1 arrest
exhibit lower lethality at a high concentration of MF
Cell particles with hypodiploid DNA content were con-
sidered to represent the proportion of dying cells. We
observed that the subset of cell lines that did display an
accumulation in G1 phase upon exposure to MF
appeared less susceptible to lethality induced by high
concentration of MF than those that did not (Figure 3A
and 3B). The mean difference in the proportion of cells
with hypodiploid DNA content between 0 h and 72 h of
treatment was calculated for each cell line, and then the
mean lethality induced by the highest concentration of
MF (40 μM) was calculated for both subsets of cell lines.
Cells accumulating in G1 phase displayed a modest
induction of lethality by 40 μM MF ranging from 5.3 ±
2.7% (PC-3) to 12.9 ± 5.1% (U87MG), with a mean of 8.7
± 1.8% (Figure 3A). Cell lines without G1 accumulation
were more sensitive to MF-induced lethality, ranging
from 17.0 ± 2.1% (SAOS-2) to 61.3 ± 7.3% (LNCaP) with
a mean lethality of 39.3 ± 6.9% (Figure 3B). In summary,
when we compared the difference between the mean
Figure 1 MF inhibits the growth of tumor cell lines of the
nervous system (A), breast (B), prostate (C), ovary (D), and
bone (E). Cells were seeded at a density appropriate for each cell
line, allowed to adhere for 24 h, and then exposed to the indicated
concentrations of MF for 72 h. At the end of the experiment, cells
were harvested by trypsinization and counted by microcytometry.
Growth curves are expressed as the percent-growth of MF-treated
cells with respect to vehicle-treated cell growth. The growth of
vehicle-treated cells was calculated as the difference between the
total number of cells at 0 h and 72 h of treatment, and was
designated as 100% growth. Data points represent the mean ± s.e.
m. of at least 3 independent experiments completed in triplicate.
Table 1 Concentration of MF needed to achieve 50%
growth inhibition (IC50) of the cell lines studied and their
doubling times (DT)
Origin Cell Line IC50 (μM) DT (h)
N. System IOMM-Lee 9.4 ± 1.2 13.9
N. System U87MG 23.2 ± 0.0 36.9
Breast MCF-7 17.7 ± 2.0 37.7
Breast MDA-MB-231 29.2 ± 1.3 33.3
Prostate LNCaP 14.1 ± 0.5 50.7
Prostate PC-3 18.5 ± 2.0 30.7
Ovary OVCAR-3 19.0 ± 1.3 55.7
Ovary SK-OV-3 12.6 ± 0.1* 36.9
Bone U-2OS 21.9 ± 2.3 29.2
Bone SAOS-2 18.7 ± 3.2 49.2
IC50 data are expressed as mean ± s.e.m of three experiments each one
performed in triplicate. DT data are the result of one experiment performed in
triplicate (see Additional file 1: Figure S1). *Date obtained from our previously
published work [14].
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proportion of cells with hypodiploid DNA content at 0 h
of treatment and after 72 h of exposure to 40 μM of MF
in all cancer cell lines, we found that a lack of observable
G1 accumulation in response to MF was associated with
significantly greater lethality.
The cytostatic effect of MF in the cancer cells studied is
associated with a decline in the activity of Cdk2
Cdk2, in association with cyclin E, is mostly responsible
for allowing cells to engage the process of DNA synth-
esis during the S phase of the cell cycle, whereas p21cip1
Figure 2 Cell cycle traverse in cancer cell lines exposed to MF. Cells were exposed to vehicle or the indicated concentrations of MF for 72
h, harvested, and stained with propidium iodide. DNA content was analyzed by microcytometry. Bars represent the mean ± s.e.m. of at least 3
independent experiments completed in triplicate, and show the percentage of cell particles with G0/G1 (A, D), S (B, E) and G2/M (C, F) DNA
content. *P < 0.05, **P < 0.01, ***P < 0.001 denote differences as compared to controls.
Figure 3 Hypodiploid DNA content in MF-treated cancer cells. Cells were exposed to vehicle or MF for 72 h, harvested, and stained with
propidium iodide. DNA content was analyzed by microcytometry. Bars represent the mean ± s.e.m. of at least 3 independent experiments
completed in triplicate, and show the percentage of cell particles with hypodiploid DNA content indicative of cell death. (A) A modest increase
in the proportion of cells with hypodiploid DNA content was observed in cell lines that responded to MF by accumulating in G1 phase (see
Figure 2). (B) A large, dose-dependent increase in the proportion of cell particles with hypodiploid DNA content was observed in cell lines that
did not show an accumulation in G1 phase in response to increasing concentrations of MF (see Figure 2). *P < 0.05, **P < 0.01, ***P < 0.001
denote difference as compared to controls.
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and p27kip1 are usually involved in inhibiting cyclin
E/Cdk2 activity [24]. Previous work in our laboratory
has pointed to a reduction in Cdk2 activity as a poten-
tial mechanism of MF-induced growth arrest [13]. We
therefore questioned whether a similar reduction in the
activity of this enzyme would be translated to this panel
of cell lines expanding various cancers. In all cells lines
exposed to either MF IC50 and/or IC75, the activity of
Cdk2 was reduced when treated with MF (Figure 4A
and 4B). The decline in Cdk2 activity induced by MF
was accompanied by increased p21cip1 abundance in
U87MG, MCF-7, OVCAR-3, LNCaP, PC-3 and SK-OV-
3 cells; increased p27kip1 levels in U87MG, MCF-7,
LNCaP, and OVCAR-3 cells; decreased levels of Cdk2 in
SAOS-2, MDA-MB-231, LNCaP, and PC-3 cells; and
reduced cyclin E in SAOS-2 and SK-OV-3 cells.
The efficacy of MF as a cytostatic agent in cancer cells is
not related to the expression of progesterone receptor,
androgen receptor, or estrogen receptor
Since MF was effective in growth inhibiting the 10
human cancer cell lines included in this study, we sub-
sequently evaluated in all cells the expression levels of
classical, nuclear PR isoforms A (PR-A) and B (PR-B),
GR isoforms alpha (GR-a) and beta (GR-b), AR, and ER
isoform alpha (ER-a) to determine whether there is a
correlation between the expression of one or more
receptor types and the sensitivity to MF-induced growth
inhibition when MF is used at cytostatic, non-lethal
doses. We were particularly interested in the role of
classical PR isoforms which are anticipated to be the
primary targets and mediators of the antiprogestin activ-
ity of MF [25]. We also decided to study the expression
Figure 4 Activity of Cdk2 and abundance of G1/S cell cycle regulatory proteins in MF-treated cancer cells. Whole-protein extracts from
cells treated with either vehicle (-), the IC50 (A) or the IC75 (B) concentrations of MF (+) for 24 h. The whole cell extracts were either
immunoprecipitated with anti-Cdk2 antibody and assayed for their capacity to phosphorylate histone H1 in vitro in the presence of [32P]ATP
(upper panels in A and B), or separated by electrophoresis and the immunoblots probed with antibodies against the cell cycle regulatory
proteins p21cip1, p27kip1, cyclin E, and Cdk2. b-actin was included as a protein loading control (lower panels in A and B). Cyclin E and Cdk2 were
immunoblotted in one membrane whereas p21cip1 and p27kip1 were blotted in a separate membrane. Consequently, each membrane was
blotted separately with anti-b-actin. This experiment was repeated twice with a similar outcome. MDA-231 means MDA-MB-231.
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of receptors in the absence or presence of MF consider-
ing that previous reports suggest that GR and PR are
modulated by the drug [17,26]. Cells were grown to 50-
70% confluence and were exposed to either vehicle or
an IC50 concentration of MF for 24 h prior to harvest-
ing. Cells were lysed, and whole protein extracts were
immunoblotted for the presence of PR-A, PR-B, GR-a,
GR-b, AR, and ER-a. Figure 5 shows the steroid hor-
mone receptor expression levels in all cell lines treated
with either vehicle or MF. In vehicle-treated cells, utiliz-
ing two different anti-human PR primary antibodies that
recognize both PR isoforms with varied efficacy, we
detected PR-A and PR-B only in MCF-7 breast cancer
cells. MCF-7 and SK-OV-3 cells expressed ER-a,
whereas only prostate LNCaP cells expressed AR. All
cell lines expressed GR-b, while GR-a appeared to be
nearly absent or at very low concentrations in MCF-7,
LNCaP, OVCAR-3, U-2OS, and SAOS-2 cells, but more
abundant in IOMM-Lee, U87MG, MDA-MD-231, PC-3,
and SK-OV-3 cells. Additionally, in response to a cyto-
static concentration of MF, we found a decrease in the
abundance of nearly all steroid hormone receptors
expressed. Both PR isoforms decreased in MCF-7 cells
following 24 h exposure to MF regardless of the PR
antibody utilized. Similarly, the expression of AR in
LNCaP prostate cancer cells exposed to MF decreased, a
slight decrease in the abundance of ER-a was observed
in MCF-7 and SK-OV-3 cells, whereas GR-a slightly
declined in some but not all cell lines treated with MF.
Conversely GR-b did not apparently change among
vehicle-treated vs. MF-treated cells in any investigated
cell line.
Discussion
We have shown that MF is able to inhibit the growth of
cancer cells derived from the nervous system, breast,
prostate, ovary, and bone, with nearly all of them not
expressing the classical, nuclear PR. Mainstream litera-
ture on the anti-cancer effect of MF assumes that it acts
as a PR antagonist, which implies that PR in the target
tissue is a pre-requisite for MF’s anti-growth activity.
Our present work challenges such a dogma, opening the
field of study to alternate, non-classical mechanisms
whereby MF operates as a cell growth inhibitor without
the necessity of nuclear PR being present or operational.
If these results were translated into the clinic, the pre-
sence or absence of classical, nuclear PR would not be
relevant and would not impact the usage of this drug
for cancer therapy.
Dose-response experiments, in which a panel of 10
cancer cell lines were exposed to increasing concentra-
tions of MF, indicated that micromolar doses of MF
were effective to inhibit the growth of malignant menin-
gioma IOMM-Lee cells, glioblastoma U87MG cells,
breast cancer MCF-7 and MDA-MB-231 cells, prostate
cancer LNCaP and PC-3 cells, ovarian cancer OVCAR-3
Figure 5 Expression of progesterone, androgen, glucocorticoid and estrogen receptors in cancer cells exposed to MF. Cells were
exposed to either vehicle or the IC50 concentration of MF specific to each cell line for 24 h. Cells were subsequently harvested, lysed, and
whole-protein extracts (50 μg for GR and AR; 100 μg for PR and ER-a) were separated by electrophoresis. Immunoblots were then probed with
the indicated antibodies (for PR: †clone hPRa7, Thermo Fisher Scientific; ‡ #1483-1, Epitomics); two commercially available antibodies for human
PR were used to strengthen the reliability of the results. b-actin was included as a control for protein loading. Because AR, GR-a and GR-b were
immunoblotted in one membrane and PR-A, PR-B and ER-a were blotted in a separate membrane, each membrane was blotted separately with
anti-b-actin. This experiment was repeated twice with similar outcome. MDA-231 means MDA-MB-231.
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and SK-OV-3 cells, and osteosarcoma U-2OS and
SAOS-2 cells; in all cell lines studied MF was cytostatic
at lower micromolar doses but lethal at higher micro-
molar concentrations. We selected the U87MG cell line
based on the aggressive nature of malignant glioma,
their reported lack of PR expression [27], and the
reported efficacy of MF in delaying their growth both in
vitro and in vivo [27]. The malignant meningioma
IOMM-Lee cell line [28] was the second line selected
from the nervous system because over 70% of meningio-
mas express PR [29], and clinical trials conducting long-
term MF treatment of patients with unresectable menin-
gioma have been promising [30,31]; yet the expression
of PR in IOMM-Lee was, to our knowledge, unknown.
Our study shows that MF growth arrests IOMM-Lee
malignant meningioma cells which lacked PR expres-
sion, suggesting that the presence of PR may not be
required for MF to operate as a growth inhibitor in this
cancer type. MCF-7 breast cancer cells are known to be
responsive to estrogen and to express PR and ER
[32-34], while triple negative MDA-MB-231 (i.e., cells
lacking PR, ER-a, and HER2) are highly aggressive [7].
Previous studies demonstrated the efficacy of MF as sin-
gle agent or in combination with 4-hydroxy-tamoxifen
in growth-inhibiting both cell lines [7,35-38]. Our data
confirm those results and find that triple negative
MDA-MB-231 cells are slightly less responsive to MF
than estrogen-responsive MCF-7 cells (Table 1). Simi-
larly in LNCaP and PC-3 prostate cancer cells, classified
respectively as androgen-sensitive and androgen-insensi-
tive, MF was efficacious in growth-inhibiting both cell
lines, confirming previous data using androgen-refrac-
tory LNCaP cell variants in vitro [8,12] and in vivo
[12,39]. PR does not appear to be related to primary
prostate tumors, but increased PR expression was
observed in prostate metastasis [40]. LNCaP cells were
reported to express PR-A and PR-B mRNA, yet PC-3
were shown not to express PR [41]. We were unable to
detect PR proteins in either of these cell lines but found
that LNCaP cells were slightly more responsive than
PC-3 cells to MF (Table 1), which may be related to the
capacity of MF to partially bind AR that are present in
LNCaP but not in PC-3 [42]. In ovarian cancer,
OVCAR-3 cells have been reported to express PR only
in vivo upon estradiol stimulation [19], while as indi-
cated earlier in the introduction, PR expression in SK-
OV-3 ovarian cancer cells is controversial. Both cell
lines were shown to be sensitive to growth inhibition by
MF in vitro [13,16] and in vivo [13], what we further
confirm in this study. Once again, the presence of PR
does not appear to be a pre-requisite for the cells to
respond to MF. Finally, we studied two osteosarcoma
cell lines of different genetic backgrounds, which were
reported to express no PR and very low levels of GR-a
[43]. We confirmed the lack of PR and the low levels of
GR-a protein but instead found GR-b with values that
were slightly higher in SAOS-2 than in U-2OS cells.
While all cell lines studied were growth inhibited by
MF, PR expression was observed only in MCF-7 breast
cancer cells known to be estradiol-responsive and to
express both PR-A and PR-B isoforms [32-34]. AR was
observed only in the androgen-dependent LNCaP pros-
tate cancer cells, which is consistent with the reported
expression of AR when these cells were first character-
ized [44]. In accordance with the reported expression of
ER in MCF-7 cells [45], we detected ER-a in this cell
line. While only a few of the cell lines included in this
study expressed PR, AR, and/or ER-a, all cell lines were
sensitive to the cytostatic and lethal effects of MF, sug-
gesting that the expression of PR, AR, and ER-a is not
required for MF to act as a growth inhibitor agent. Pre-
sence of MF reduced the expression of PR and ER-a in
MCF-7 cells, AR in LNCaP cells, and ER-a in SK-OV-3
cells further discouraging the role of these receptors as
mediators of the growth inhibitory effect of MF given
that the cytostatic property of MF can be maintained
long after those receptors are down-regulated.
Our previous studies in ovarian cancer cells indicated
that MF-induced growth inhibition occurs through G1
cell cycle arrest and a profound inhibition of the G1/S
kinase, Cdk2 [13]. In the present study, analysis of cell
cycle kinetics following 72 h exposure of each cell line
to MF showed the accumulation of cells with G1 phase
DNA content in U87MG, MCF-7, PC-3, and SK-OV-3
cells, yet 6 cell lines in this study did not respond to
MF with G1 arrest. Instead, we observed either a main-
tenance of the proportion of cells in each phase of the
cell cycle up to a lethal concentration of MF (IOMM-
Lee, MDA-MB-231, U-2OS, and SAOS-2 cells), or a
steady decline in the proportion of cells in each phase
of the cell cycle beginning at low concentrations of MF
with a corresponding increase in cells with hypodiploid
DNA content (LNCaP and OVCAR-3 cells). Despite
these differences, the decline in the activity of Cdk2
within 24 h of exposure to MF was a commonality
among the 10 cell lines studied (Figure 4), as we have
shown in ovarian cancer cells for MF [13] and more
recently for two other antiprogestins, ORG-31710 and
CDB-2914 [46].
In this work evidence has ruled out that classical,
nuclear PR must be expressed in a cancer cell to
respond to the cytostatic activity of the so-classified
antiprogestin MF. Further studies will need to be con-
ducted to define the molecular targets and mediators of
MF’s action. Though all cell lines studied express vari-
able levels of GR-a and GR-b, we could not find any
correlation between the relative growth inhibitory
response of the cells to MF and the relative abundance
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of GR-a (r = - 0.1831; P = 0.612), GR-b ( r = 0.0834; P
= 0.818) or the ratio GR-a/GR-b (r = - 0.2366; P =
0.510) as determined by densitometry analysis of the
Western blots presented in Figure 5 and corrected by b-
actin loading. MF was designed in the mid-1980s with
the purpose of treating Cushing’s syndrome by working
as a potent anti-glucorticoid agent [4,47]. Indeed MF
binds GR-a with mostly antagonistic activity; yet it may
have agonistic potency depending on the concentration
of GR in the cell [48]. Although GR-b has been consid-
ered a dominant-negative regulator of GR-a [49-51], it
was also reported that MF was the only compound of
57 potential natural and synthetic ligands to bind to the
GR-b receptor isoform, and that interaction of GR-b
with MF led to its nuclear translocation [52]. Addition-
ally, this latter study found that despite its classification
as a dominant-negative isoform lacking transcriptional
activity, GR-b was capable of regulating gene expression
in the absence of GR-a, and this activity was modulated
by interaction with MF. A more recent study also
reported intrinsic transcriptional activity of GR-b inde-
pendent of GR-a, but neither found an association
between MF binding and nuclear translocation of GR-b
nor could detect modulation of GR-b transcriptional
activity by MF [53], adding controversy to the actual
activity of MF on GR-b. This evidence and our results
strongly suggest that further studies need to be con-
ducted to determine any role of either GR isoform on
the anti-growth activity of MF.
A possibility exists in that the newly discovered pro-
gesterone receptor membrane component 1 (PGRMC1)
[54,55] or the family of membrane PRs (mPRa, b, g, δ,
ε) [55-57] mediate the anti-tumor effects of MF. For
instance, PGRMC1 expression increases while cognate,
nuclear PR decreases in advanced stages of ovarian can-
cer, and overexpression of PGRMC1 interferes with the
lethality of cisplatin, suggesting a survival role for
PGRMC1 in ovarian cancer development [58]. In a
panel of ovarian cancer cell lines expressing abundant
mPRa, mPRb, and mPRg, but not classical nuclear PR-A
and -B, exposure to progesterone mediated the expres-
sion of pro-apoptotic proteins via activation of JNK and
p38 MAPKs [22]. Given that at micromolar concentra-
tions MF functions as an agonist on both mPRa and
mPRg when expressed in yeast [59], it is conceivable
that MF may mediate antiproliferation of cancer cells
acting as an agonist of mPRs.
At micromolar doses, MF may have an alternate
mechanism of action. For instance MF has a potent
antioxidant effect when used at micromolar concentra-
tions and attributed to the presence of the dimethyla-
mino phenyl side chain of the molecule [60]. In
endometrial cells and macrophages, the growth inhibi-
tory effect of MF was partially attributed to the
antioxidant property of the compound [61,62]. A puta-
tive antioxidant property of MF in cancer cells would be
relevant in the context of p21cip1 induced G1 arrest as
p21cip1 has been shown to be induced by some antioxi-
dants in a p53-independent manner [63,64]. Another
potential mechanism involved in MF’s anti-growth activ-
ity is the induction of stress of the endoplasmic reticu-
lum. For instance a recent study showed that MF
induced an atypical unfolded protein response (UPR) in
non-small lung cell carcinoma cells [65].
Conclusions
This study has shown that the canonical, nuclear PR is
not required for MF to successfully inhibit the growth
of a panel of 10 cancer cell lines of different genetic
backgrounds, hormone-responsiveness, and tissues of
origin. Our study is limited only to eliminate the dogma
that classical PR should be present to consider the use
of MF in cancer therapy. However, the present results
warrant mechanistic studies to uncover the ultimate
mediators of MF’s anti-proliferative activity in cancer
cells. The role of mPRs, PGRMC1 and GR-b as media-
tors of MF anti-growth activity needs investigation.
Furthermore the role of the endoplasmic reticulum
responding to MF triggering the UPR, what could lead
to either survival with cytostasis or death depending
upon the concentration of MF, is a provoking hypoth-
esis that deserves to be investigated.
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Additional File 1: Figure 1S. Growth curves displaying proliferation
of vehicle-treated cancer cells as a function of time in culture. Cells
were seeded at a density equivalent to that used in dose-response
experiments, and were allowed to grow in culture for 96 h. Triplicate
wells were harvested by trypsinization and counted by microcytometry
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